SEER is an authoritative source of information on cancer incidence and survival in the United States. SEER currently collects and publishes cancer incidence and survival data from population-based cancer registries covering approximately 28 percent of the U.S. population.
Characterized by the presence of >20% blasts in the bone marrow or peripheral blood. There is evidence of maturation (>=10% maturing cells of neutrophil lineage); cells of monocyte lineage compromise <20% of BM cells.
The provisional diagnosis during workup may include RA with excess blasts, AML without maturation, AML with maturation, and acute myelomonocytic leukemia.